Adaptive Biotechnologies (ADPT) said Tuesday that Medicare administrative contractor Palmetto GBA has expanded coverage of the biotechnology company's clonoSEQ test service to monitor mantle cell lymphoma treatment-free remission.

The expanded service allows patients who have completed treatment for mantle cell lymphoma to have coverage for receiving clonoSEQ testing every six months for up to five years during treatment-free remission, and annual testing thereafter until disease recurrance is detected, the company said.